Drug makers increase cashable assets amid economic woes and unpredictable variables

Published: 2013-09-04 07:00:00

Updated: 2013-09-04 07:00:00

Influenced by persistent market uncertainty together with worsening business conditions, Korean pharmaceutical firms are choosing to hold more of their earnings in cashable assets as they find it harder to invest.

Cashable assets include cash, cash equivalents and other short-term financial pr...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK